Skip to main content
. 2020 Aug 4;10:1144. doi: 10.3389/fonc.2020.01144

Table 6.

Ki67 analysis considering a cut-off point of 3% (45), in relation to epidemiological variables, immunomarkers, imaging, histopathology, and clinical evolution.

Variable Ki67 Total p-value
≤3% >3%
Sex Female n 48 21 69 0.938
Male % 71.6 72.4 71.9
Male n 19 8 27
% 28.4 27.6 28.1
Total n 67 29 96
ER %cell n 65 27 92 0.509
% 98.5 96.4 97.9
+ n 1 1 2
% 1.5 3.6 2.1
Total n 66 28 94
PR %cell n 22 13 35 0.273
% 34.4 46.4 38.0
+ n 42 15 57
% 65.6 53.6 62.0
Total n 64 28 92
p53 n 4 3 7 0.433
% 6.1 10.3 7.4
+ n 62 26 88
% 93.9 89.7 92.6
Total n 66 29 95
AR %cell n 62 25 87 0.361
% 95.4 89.3 93.5
+ n 3 3 6
% 4.6 10.7 6.5
Total n 65 28 93
Size Medium n 17 10 27 0.367
% 29.8 40.0 32.9
Large n 40 15 55
% 70.2 60.0 67.1
Total n 57 25 82
Calcification No n 62 24 86 0.163
% 92.5 82.8 89.6
Yes n 5 5 10
% 7.5 17.2 10.4
Total n 67 29 96
Peritumoral edema No n 49 19 68 0.451
% 73.1 65.5 70.8
Yes n 18 10 28
% 26.9 34.5 29.2
Total n 67 29 96
Recurrence/
regrowth
No n 60 22 82 0.114
% 89.6 75.9 85.4
Yes n 7 7 14
% 10.4 24.1 14.6
Total n 67 29 96
HLA-E %cell n 3 0 3 HLA-E %cell
% 4.8 0.0 3.3
+ n 59 28 87
% 95.2 100.0 96.7
Total n 62 28 90 Total
Follow-up Alive n 52 23 75 0.853
% 77.6 79.3 78.1
Dead n 15 6 21
% 22.4 20.7 21.9
Total n 67 29 96
Subtypes of meningiomas Fibrous n 7 0 7 0.005
% 11.7 0.0 8.0
Meningothelial n 48 19 67
% 80.0 67.9 76.1
Transitional n 5 9 14

Ki67, cell proliferation index by MIB-1/Ki67 monoclonal antibody; ER, estrogen receptor; PR, progesterone receptor; p53, nuclear phosphoprotein; AR, androgen receptor; HLA-E, human leukocyte antigen E. Chi-square test.